Site and intensity of neuroinflammation were correlated with tau pathology [13] and clinical severity [14] on positron emission tomography; and cerebrospinal fluid (CSF) cytokines suggesting microglial activation including tumor necrosis factor alpha, interleukin (IL)-1β, and IL-6 were elevated in PSP patients compared to controls [15]. This evidence concerns the gene MAPT and supranuclear palsy, progressive, 1.